Sign In
Buy ACOR
$0.661
+0 (+0%)
At Close: Jul 10, 2024
European Respiratory Devices Market 2020 by Product, End-user and Region - ResearchAndMarkets.com
08:27am, Tuesday, 21'st Apr 2020
Press release content from Business Wire. The AP news staff was not involved in its creation.
Acorda Therapeutics (ACOR) Flat As Market Gains: What You Should Know
09:45pm, Thursday, 16'th Apr 2020
Acorda Therapeutics (ACOR) closed the most recent trading day at $1.06, making no change from the previous trading session.
Acorda Therapeutics (ACOR) Flat As Market Gains: What You Should Know
09:45pm, Thursday, 16'th Apr 2020
Acorda Therapeutics (ACOR) closed the most recent trading day at $1.06, making no change from the previous trading session.
Solid Biosciences Announces Appointment of Ian F. Smith to its Board of Directors
11:00am, Thursday, 16'th Apr 2020
Solid Biosciences Inc. (SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy, announced today the appointment of Ian F. Smith to its board of direct
Acorda Therapeutics (ACOR) Flat As Market Gains: What You Should Know
12:00am, Thursday, 16'th Apr 2020Tech sector boosts the market: ASX closed 1.9% higher
07:18am, Tuesday, 14'th Apr 2020
14 Apr 2020 - It has been a mostly positive day of trade for the ASX after a small dip in early morning trade the local bourse managed to close 1.9% higher. As for the sectors today Infotech led the d
USFDA grants fee waiver to Cyclopharm (ASX:CYC) for Technegas application
02:02am, Tuesday, 14'th Apr 2020
14 Apr 2020 - Cyclopharm (ASX:CYC) is pleased to announce that the United States Food and Drug Administration (USFDA) has granted the Company a full application fee waiver of USD $2.9 million related
$39.34 Million in Sales Expected for Acorda Therapeutics Inc (NASDAQ:ACOR) This Quarter
08:18am, Sunday, 12'th Apr 2020
Analysts expect that Acorda Therapeutics Inc (NASDAQ:ACOR) will post $39.34 million in sales for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates fo
Mesoblast (ASX:MSB) see trials for COVID-19 lung distress
01:00am, Thursday, 09'th Apr 2020
09 Apr 2020 - Mesoblast (ASX:MSB) today announced that its stem cell product candidate remestemcel-L will be formally evaluated in a randomized, placebo-controlled trial in patients with acute respira
Immunomedics' Sacituzumab Govitecan Gets Fast Track Tag for UC
03:36pm, Wednesday, 08'th Apr 2020
The FDA bestows a fast track status on Immunomedics' (IMMU) sacituzumab govitecan for treating adult patients with locally advanced or metastatic urothelial cancer (mUC).
Immunomedics' Sacituzumab Govitecan Gets Fast Track Tag for UC
03:36pm, Wednesday, 08'th Apr 2020
The FDA bestows a fast track status on Immunomedics' (IMMU) sacituzumab govitecan for treating adult patients with locally advanced or metastatic urothelial cancer (mUC).
Immunomedics' Sacituzumab Govitecan Gets Fast Track Tag for UC
12:00am, Wednesday, 08'th Apr 2020Acorda Therapeutics (ACOR) Stock Moves -0.11%: What You Should Know
09:50pm, Tuesday, 07'th Apr 2020
Acorda Therapeutics (ACOR) closed the most recent trading day at $0.93, moving -0.11% from the previous trading session.
Acorda Therapeutics (ACOR) Stock Moves -0.11%: What You Should Know
09:50pm, Tuesday, 07'th Apr 2020
Acorda Therapeutics (ACOR) closed the most recent trading day at $0.93, moving -0.11% from the previous trading session.
